

Effects of GSK v Teva Ripple after SCOTUS Denies Cert

May 23, 2023

ATTORNEYS

Blau, Ross

Haroon, Gulrukh

Landmon, Chad

PRACTICE AREAS

Intellectual Property

Patents

Chad Landmon, Ross Blau, and Gulrukh Haroon

Life Sciences IP Review

Axinn partner Chad Landmon and associates Ross Blau and Gulrukh Haroon co-authored the *Life Sciences IP Review* article, "Effects of GSK v Teva Ripple after SCOTUS Denies Cert."

[Click here](#) to access the publication. A subscription is required.